Ketamine for Methamphetamine Use Disorder

Launched by UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER · Jul 3, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of intravenous (IV) ketamine as a treatment for adults with moderate to severe methamphetamine use disorder (MUD). Researchers want to find out if ketamine works better than another medication called midazolam in helping people reduce or stop their methamphetamine use. The study will last for 12 weeks and will involve 120 adults who will receive either ketamine or midazolam during six weeks of treatment.

To participate in this trial, individuals need to be between 18 and 65 years old, be able to understand and communicate in English, and be willing to reduce or stop using methamphetamine. It's important that they have a diagnosed methamphetamine use disorder and use effective birth control if they can become pregnant. Participants will not be eligible if they have recently been involved in other addiction studies, are currently incarcerated, have surgery planned, or are pregnant or breastfeeding. Throughout the study, participants will receive care and support as they work towards their goals.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• Study participants must:
• • 1. Be 18 to 65 years old
• • 2. Be able to sufficiently understand, speak, and read English
• • 3. Be interested in reducing or stopping methamphetamine use
• • 4. Meet criteria for methamphetamine use disorder
• • 5. Use acceptable methods of contraception during participation in the study
• • Exclusion criteria
• Study participants must not:
• • 1. Have been in a research study of pharmacological or behavioral treatment for addiction within 6 months prior to written informed consent
• • 2. Be currently in jail, prison, or inpatient overnight facility as required by court of law
• • 3. Have upcoming surgery planned or scheduled
• • 4. Be currently pregnant, breastfeeding, or planning on conception, if biologically female
• • Additional inclusion and exclusion criteria will be assessed by the study investigators at the screening visit.